Clinical Trial

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy and safety of 9MW2821 and chemotherapy in participants with recurrent or metastatic cervical cancer who progressed on or after platinum-based chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-14.
Trial Details
NCT Number NCT06692166
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Cervical Cancer
Enrollment 420 participants
Start Date 2024-09-10
Primary Completion 2027-12-09 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-22